GRAIL (GRAL) — FDA Molecular & Clinical Genetics panel votes 7-2-1 that Galleri multi-cancer blood test's benefits outweigh risks on Wed Sept 23; 10-0 safety, 6-4 effectiveness; stock halted all session, +36% in the two days before, -3.23% to <meta name="viewport" content="width=device-width, initial-scale=1.0" />05.01 Thu

05.01 Thu" /> 05.01 Thu" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.